Nanocarrier-Enabled siRNA Therapy for Pulmonary Fibrosis: Pharmacological Rationale, Delivery Barriers, and Translational Opportunities
Abstract Pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF), is a progressive interstitial lung disease caused by failed epithelial repair, persistent fibroblast activation, immune dysregulation, and extracellular matrix (ECM) remodeling. Nintedanib and pirfenidone slow functional decline but do not r...